NAMPT and NAD+ Biosynthesis

What NAMPT does

NAMPT (nicotinamide phosphoribosyltransferase) is the enzyme that carries out the first step of the NAD+ salvage pathway: converting nicotinamide (NAM) into NMN.[1] NMN is then converted into NAD+ by a second enzyme, NMNAT — covered separately on NMNAT Enzymes Explained. NAMPT's role in this specific conversion is well-characterized, established enzymology, not a contested or preliminary finding.[1]

Why NAMPT is called "rate-limiting" — and what that term does and doesn't mean

NAMPT is frequently described as the rate-limiting enzyme of the salvage pathway, meaning that under many experimental conditions, the amount and activity of NAMPT — more than the downstream NMNAT step — determines how quickly the pathway can produce new NAD+.[1] This is a statement about enzyme kinetics within a cell, not a statement about what happens when NMN — the product one step downstream of NAMPT — is supplied directly to the body from outside. Supplying NMN as a supplement is, by definition, an attempt to bypass the NAMPT step entirely, so NAMPT's rate-limiting status is not itself evidence about whether that bypass strategy changes NAD+ levels or produces a health benefit in humans; that separate question is addressed with actual trial data on NMN Dosage and NMN Safety and Side Effects.

Intracellular NAMPT vs. extracellular NAMPT

NAMPT exists in two distinct pools that behave differently and should not be conflated. Intracellular NAMPT (iNAMPT) is the form that carries out NAD+ salvage inside the cell, as described above.[1] A separate, secreted form — extracellular NAMPT (eNAMPT), also historically called visfatin or PBEF — is released by adipose tissue, immune cells, and other cell types into the bloodstream, where research indicates it can act less like a metabolic enzyme and more like a signaling molecule or cytokine, engaging cell-surface receptors and inflammatory pathways.[2] Elevated circulating eNAMPT has been associated with obesity, diabetes, and other inflammatory and metabolic conditions in observational research, but the precise mechanisms of eNAMPT secretion and its full range of physiological functions remain an active, debated area of research rather than settled science.[2] This eNAMPT biology is a distinct research area from the NMN-supplement question this hub otherwise covers, and should not be read as supporting or undermining any claim about oral NMN.

Tissue and context dependence

NAMPT expression is not uniform across the body. In mice, it is comparatively high in brown adipose tissue, liver, and kidney; moderate in white adipose tissue, lung, spleen, testes, and skeletal muscle; and undetectable in brain and pancreas.[3] Expression also shifts with physiological state in tissue-specific ways — for example, adipose NAMPT decreases with obesity, while skeletal-muscle NAMPT increases with exercise training.[3] This context-dependence is one reason findings about NAMPT in one tissue don't automatically generalize to every other tissue, and is part of why simple, universal claims about "boosting NAMPT" oversimplify an enzyme whose behavior is genuinely tissue-specific.

What this page is not claiming

NAMPT's central role in NAD+ salvage is established biochemistry. That NAMPT is important to cellular NAD+ maintenance does not, by itself, establish that NMN supplementation — which supplies the enzyme's downstream product rather than acting on NAMPT itself — produces any specific measurable benefit in healthy humans. Nothing on this page should be read as a claim about NAMPT-targeted longevity or anti-aging effects.

Related reading

For the pathway NAMPT begins, see The NAD+ Salvage Pathway. For the enzyme that finishes the conversion to NAD+, see NMNAT Enzymes Explained. For how NMN itself gets into cells — a separate and more disputed question — see NMN Transport and Cellular Uptake.